Citi analyst Joanne Wuensch lowered the firm’s price target on Tandem Diabetes to $31 from $33 and keeps a Neutral rating on the shares. The analyst adjusted price targets in the medical technology space post the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNDM:
- Tandem Diabetes price target lowered to $32 from $33 at Baird
- Tandem Diabetes price target lowered to $62 from $71 at Barclays
- Tandem Diabetes price target lowered to $34 from $52 at TD Cowen
- Tandem Diabetes downgraded to Neutral from Buy at Citi
- Tandem Diabetes price target lowered to $33 from $38 at Baird